FRA:BIO3 - Deutsche Boerse Ag - DE0005227235 - Currency: EUR
FRA:BIO3 (4/14/2025, 2:07:12 PM)
30
0 (0%)
The current stock price of BIO3.DE is 30 EUR. In the past month the price increased by 11.11%. In the past year, price decreased by -23.66%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
4AB.DE | ABBVIE INC | 18.12 | 285.34B | ||
AMG.DE | AMGEN INC | 14.06 | 131.64B | ||
GIS.DE | GILEAD SCIENCES INC | 22.38 | 112.98B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | 1728.6 | 111.10B | ||
ARGX.BR | ARGENX SE | 352.5 | 32.72B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 24.57B | ||
IDP.DE | BIOGEN INC | 7.29 | 15.44B | ||
0QF.DE | MODERNA INC | N/A | 9.46B | ||
1MRNA.MI | MODERNA INC | N/A | 9.08B | ||
BIO.DE | BIOTEST AG | 24.8 | 1.68B | ||
GLPG.AS | GALAPAGOS NV | N/A | 1.54B | ||
AZT.OL | ARCTICZYMES TECHNOLOGIES ASA | 124.29 | 888.62M |
Biotest AG is a DE-based company operating in Biotechnology industry. The company is headquartered in Dreieich, Hessen. Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology, and intensive care medicine. The company develops, manufactures, and markets immunoglobulin, coagulation factors, and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition, the Company develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus, which are produced by recombinant technologies.
BIOTEST AG-VORZUGSAKTIEN
Landsteinerstr. 5
Dreieich HESSEN DE
Employees: 2464
Company Website: https://www.biotest.com/
Phone: 4961038010
The current stock price of BIO3.DE is 30 EUR.
The exchange symbol of BIOTEST AG-VORZUGSAKTIEN is BIO3 and it is listed on the Deutsche Boerse Ag exchange.
BIO3.DE stock is listed on the Deutsche Boerse Ag exchange.
BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) has a market capitalization of 1.19B EUR. This makes BIO3.DE a Small Cap stock.
BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) currently has 2464 employees.
BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) has a support level at 28.13 and a resistance level at 30.01. Check the full technical report for a detailed analysis of BIO3.DE support and resistance levels.
The Revenue of BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) is expected to decline by -6.17% in the next year. Check the estimates tab for more information on the BIO3.DE EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
BIO3.DE does not pay a dividend.
BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) will report earnings on 2025-05-05.
The PE ratio for BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) is 17.54. This is based on the reported non-GAAP earnings per share of 1.71 and the current share price of 30 EUR. Check the full fundamental report for a full analysis of the valuation metrics for BIO3.DE.
ChartMill assigns a technical rating of 2 / 10 to BIO3.DE. When comparing the yearly performance of all stocks, BIO3.DE is a bad performer in the overall market: 83.56% of all stocks are doing better.
ChartMill assigns a fundamental rating of 5 / 10 to BIO3.DE. BIO3.DE has only an average score on both its financial health and profitability.
Over the last trailing twelve months BIO3.DE reported a non-GAAP Earnings per Share(EPS) of 1.71. The EPS increased by 32.71% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 23.75% | ||
ROA | 13.97% | ||
ROE | 35.86% | ||
Debt/Equity | 0.8 |
ChartMill assigns a Buy % Consensus number of 46% to BIO3.DE. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of -103.15% and a revenue growth -6.17% for BIO3.DE